Oscotec Inc.

NEWSROOM

Notice Press Releases Publications IR Materials

Home NEWSROOM Press Releases

T기본글꼴

✔ 사이트를 뷰어로 보기 검색 Write

Oscotec/ADEL Initiates First-in-Human Dosing in Ph1 of Anti-MTBR Tau Antibody ADEL-Y01 In Alzheimer's Disease

Date2024-02-23 Mediayahoo! finance PipelineOscotec

Read More
Oscotec/ADEL Announce FDA Clearance of IND Application of ADEL-Y01 for the Treatment of Alzheimer's Disease

Date2023-09-14 MediaBiospace PipelineOscotec

Read More
Other news to note for March 2, 2021

Date2021-03-02 MediaBioWorld PipelineOscotec

Read More
Oscotec and Beactica Therapeutics announce license and collaboration agreement to develop new cancer drug

Date2021-03-02 MediaCISION PipelineOscotec

Read More
Janssen Announces Phase 1 Results for Bispecific Antibody Amivantamab in the treatment of Patients with Advanced Non-Small Cell Lung Cancer Harboring Exon 20 Insertion Mutations

Date2020-05-18 MediaBioSpace PipelineLazertinib

Read More
Lazertinib Shows Promising Antitumor Activity in Patients With EGFR+ NSCLC

Date2019-12-14 MediaTargeted Oncology PipelineLazertinib

Read More
Yuhan to start phase-3 trial on lung cancer drug Lazertinib

Date2019-12-12 MediaKBR (; Korea Biomedical Review) PipelineLazertinib

Read More
"Global Immune Thrombocytopenia (ITP) Market Insights, Epidemiology, and Forecasts, 2017-2028 : Focus on United States, Germany, Spain, Italy, France, and the United Kingdom, and Japan"

Date2019-12-02 MediaPRNewswire PipelineGenosco

Read More
AXL receptor tyrosine kinase as a promising anti-cancer approach: functions, molecular mechanisms and clinical applications

Date2019-11-04 MediaMolecular Cancer PipelineSKI-G-801

Read More
Lazertinib in patients with EGFR mutation-positive advanced non-small-cell lung cancer: results from the dose escalation and dose expansion parts of a first-in-human, open-label, multicentre, phase 1-2 study

Date2019-11-04 MediaTHE LANCET ONCOLOGY PipelineLazertinib

Read More
Abstract 2010 : SKI-G-801, an AXL kinase inhibitor, blocks metastasis and induces anti-tumor immune response in various syngeneic cancer models

Date2019-07-01 MediaCANCER RESEARCH PipelineSKI-G-801

Read More
Oscotec wins exception policy for continued R&D for new drugs

Date2019-06-25 MediaKBR (; Korea Biomedical Review) PipelineOscotec

Read More

주주님들께 드리는 글	2022.08.30
SCI Journal - SKI-G-8...	2022.02.16
FLT3/AXL Inhibitor (A...	2020.06.22

Translating science into medicine

PRESS

NEWSROOM

Oscotec/ADEL Initiates First-in-Human Dosing in Ph1 of Anti-MTBR Tau Antibody ADEL-Y01 In Alzheimer's Disease

Oscotec/ADEL Announce FDA Clearance of IND Application of ADEL-Y01 for the Treatment of Alzheimer's Disease

Other news to note for March 2, 2021

Oscotec and Beactica Therapeutics announce license and collaboration agreement to develop new cancer drug

Janssen Announces Phase 1 Results for Bispecific Antibody Amivantamab in the treatment of Patients with Advanced Non-Small Cell Lung Cancer Harboring Exon 20 Insertion Mutations

Lazertinib Shows Promising Antitumor Activity in Patients With EGFR+ NSCLC

Yuhan to start phase-3 trial on lung cancer drug Lazertinib

"Global Immune Thrombocytopenia (ITP) Market Insights, Epidemiology, and Forecasts, 2017-2028 : Focus on United States, Germany, Spain, Italy, France, and the United Kingdom, and Japan"

AXL receptor tyrosine kinase as a promising anti-cancer approach: functions, molecular mechanisms and clinical applications

Lazertinib in patients with EGFR mutation-positive advanced non-small-cell lung cancer: results from the dose escalation and dose expansion parts of a first-in-human, open-label, multicentre, phase 1-2 study

Abstract 2010 : SKI-G-801, an AXL kinase inhibitor, blocks metastasis and induces anti-tumor immune response in various syngeneic cancer models

Oscotec wins exception policy for continued R&D for new drugs

To inquire